Page 50 - Hormel Report 2023

James Robinson, PhD
“Our research is helping to identify the causes of
pediatric brain tumors and melanoma and points the
way to improved methods of diagnosis and treatment.”
James Robinson
50 | THE HORMEL INSTITUTE // UNIVERSITY OF MINNESOTA Cell Signaling and Tumorigenesis
ASSOCIATE PROFESSOR
Our lab is committed to groundbreaking research in the field of cancer biology. We are primarily located at The Hormel
Institute, University of Minnesota in Austin, MN. Our research endeavors have attracted various prestigious awards, which have played a pivotal role in the progress we’ve made in studying pedi- atric gliomas and melanoma. This document aims to summarize our active, pending, and proposed research awards that fund these vital projects.
Mechanistic Dissection of the K27M His- tone Mutation in Pediatric Gliomagenesis
This project is supported by a generous award (Robinson) from the Minnesota Partnership for Biotechnology and Medical Genomics Collaborative Research Grant. With a total
award amount of $953,419, the initiative aims to shed light on the mutations in the H3.3 gene and their contribution to the formation of pediatric gliomas.
Targeting Chromosome Instability and the cGAS-STING Network in Pediatric Mid- Line Gliomas (K27M Mutant)
Supported by an award from the Department of Defense (Hinchcliffe), with a total funding amount of $785,000, this project focuses on gathering preliminary data for a future Phase I clinical study. The study will evaluate the safety and efficacy of Ganciclovir, either alone or in combination with AZD7762, for patients suffering from K27M midline gliomas.